HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

Item
http://www.wikidata.org/entity/Q38885415
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinomaAdvances in sarcoma diagnostics and treatmentNotch activation drives adipocyte dedifferentiation and tumorigenic transformation in miceDownregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Therapeutic applications of histone deacetylase inhibitors in sarcoma.Does PTEN gene mutation play any role in Li-Fraumeni syndrome.Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.
P2860

HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

Item
http://www.wikidata.org/entity/Q38885415
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
HDACi inhibits liposarcoma via ...... tive of p53 mutational status.
@en
type
label
HDACi inhibits liposarcoma via ...... tive of p53 mutational status.
@en
prefLabel
HDACi inhibits liposarcoma via ...... tive of p53 mutational status.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
HDACi inhibits liposarcoma via ...... tive of p53 mutational status.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932